We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 146

Pfizer v Ranbaxy; 55.2 proceeding; October 5, 2007 - atorvastatin
  • Gowling Lafleur Henderson LLP
  • Canada
  • October 25 2007

The trial judge granted prohibition in respect of one patent claiming a novel crystalline form of atorvastatin (the "crystalline form patent") and denied prohibition in respect of another patent claiming a novel process for making atorvastatin (the "process patent"


AstraZeneca v Novopharm, motion to adduce video-recordings of cross-examinations of expert witnesses in a PMNOC Regulations case
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

AstraZeneca brought a motion seeking an order that video-recordings of cross-examinations of expert witnesses in the proceedings be filed as part of the Application Record and available at the hearing


Sanofi v ratiopharm, PMNOC Regulations decision irbesartan, March 5, 2010
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

Sanofi sought an order prohibiting the granting of a NOC to ratiopharm


Supreme Court denies leave to appeal in Section 8 damage case
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 12 2010

Recently, the Supreme Court denied Apotex's leave application for leave to appeal to the Supreme Court of Canada in respect of Apotex's case seeking damages for alleged delays due to a proceeding brought by Merck under the Patented Medicines (Notice of Compliance Regulations) ("NOC Regulations"


PMPRB issues discussion paper on options to address the Federal Court decision in LEO Pharma
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 6 2008

The Patented Medicine Prices Review Board (PMPRB) has issued a discussion paper outlining a series of options to address the implications of the Federal Court of Canada decision in the LEO Pharma case


Data protection: defining innovative drug in Canada
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 22 2013

Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement Canada's 1994


Servier v Apotex, interlocutory motion in an infringement action; November 19, 2007 - perindopril
  • Gowling Lafleur Henderson LLP
  • Canada
  • December 6 2007

By this motion, two additional innovator companies sought leave to be added as defendants to Apotex's counterclaim against Servier under the Competition Act


Purdue v Pharmascience, interlocutory motion on a Section 55.2 proceeding; November 15, 2007 - oxycodone
  • Gowling Lafleur Henderson LLP
  • Canada
  • December 6 2007

The Applicants brought a motion to reverse the order of evidence in the s.55.2 proceeding


Apotex v the Gov. in Council et al; the Minister of Health et al v CPGA, appeal of decisions on motions to strike judicial reviews
  • Gowling Lafleur Henderson LLP
  • Canada
  • December 6 2007

In a pair of decisions, the Court of Appeal has indicated that judicial review applications brought by CGPA and Apotex attacking the vires of the Data Protection Regulations brought into force in October 2006 may be heard


Recent cases
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 8 2008

The trial judge determined that the Minister did not err in interpreting the NOC and the patent and thus dismissed the application for judicial review seeking to have the patent listed on the Patent Register